Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More
Xconomy
OCTOBER 7, 2016
. —Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. —The 2016 Nobel Prize for Physiology or Medicine went to Yoshinori Ohsumi of the Tokyo Institute of Technology.
77 
Let's personalize your content